With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...
HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...
The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...
Alnylam (ALNY) announced the planned expansion of its manufacturing facility in Norton, Massachusetts. The company is preparing to invest $250M to ...
Six firms are set to join the Nasdaq 100 Index as part of its annual reconstitution, the benchmark’s overseer said Friday.
Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
An Alnylam Pharmaceuticals drug that treats nerve pain caused by an inherited protein disorder now has results from a pivotal clinical trial showing the drug also helps patients suffering the ...
The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...
Alnylam must wait a few months longer for a verdict on its potential blockbuster-in-waiting vutrisiran. The U.S. FDA has slapped a three-month delay on its review of the RNA interference (RNAi) ...
The age of RNA interference drugs has arrived. Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback